Literature DB >> 15503107

Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families.

Paul W Wirtz1, Jennifer Bradshaw, Axel R Wintzen, Jan J Verschuuren.   

Abstract

In view of the clustering of autoimmune diseases (AIDs), we studied the frequency and nature of additional AIDs in patients with the Lambert-Eaton myasthenic syndrome (LEMS) and their family members, in both small cell lung carcinoma (SCLC) related and non-tumour (NT) related cases. Additional AIDs in patients with LEMS were assessed by interviewing the patient and studying the medical record. Family histories up to second-degree family members were established by interviewing patients, controls and family members. Forty-four patients with LEMS were assessed, of whom eighteen (41%) had SCLC. In the NT group seven patients (27%) had an additional AID, in the SCLC group two (11 %) (p=0.20). Thyroid disorder (five patients) and insulin dependent diabetes mellitus (two patients) were the most common AIDs. AIDs were significantly more frequent in families of patients with NT-LEMS (64%) than in control families (27%) (p=0.002), which was not found in SCLC-LEMS (36%, p=0.53). Affected family members were linked to the NT-LEMS patient through the maternal line in all cases. In conclusion, AIDs were more frequently found in LEMS patients without a tumour and their families, which could not be shown for SCLC-LEMS. This suggests that NT-LEMS shares immunogenetic factors with other AIDs. In families of NT-LEMS, a remarkable preponderance of maternal inheritance was seen, as has been reported previously in myasthenia gravis.

Entities:  

Mesh:

Year:  2004        PMID: 15503107     DOI: 10.1007/s00415-004-0528-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma.

Authors:  Paul W Wirtz; Nick Willcox; Bart O Roep; Bethan Lang; Axel R Wintzen; John Newsom-Davis; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

Review 2.  Susceptibility to type I diabetes: HLA-DQ and DR revisited.

Authors:  J X She
Journal:  Immunol Today       Date:  1996-07

3.  Genetic factors in myasthenia gravis: a family study.

Authors:  L Kerzin-Storrar; R A Metcalfe; P A Dyer; G Kowalska; I Ferguson; R Harris
Journal:  Neurology       Date:  1988-01       Impact factor: 9.910

Review 4.  [Incidence and prevalence of genetically-determined disorders in The Netherlands; a literature study].

Authors:  J B Verheij; M Edens; M C Cornel; J W Groothoff; L P ten Kate
Journal:  Ned Tijdschr Geneeskd       Date:  1994-01-08

Review 5.  Genetic susceptibility to the development of autoimmune disease.

Authors:  J Heward; S C Gough
Journal:  Clin Sci (Lond)       Date:  1997-12       Impact factor: 6.124

6.  Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.

Authors:  R W Tim; J M Massey; D B Sanders
Journal:  Neurology       Date:  2000-06-13       Impact factor: 9.910

7.  Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma.

Authors:  S D Meriney; S C Hulsizer; V A Lennon; A D Grinnell
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

8.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

9.  Autoimmunity in the Lambert-Eaton myasthenic syndrome.

Authors:  V A Lennon; E H Lambert; S Whittingham; V Fairbanks
Journal:  Muscle Nerve       Date:  1982       Impact factor: 3.217

10.  The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.

Authors:  Paul W Wirtz; Marianne G Nijnuis; Mohammad Sotodeh; Luc N A Willems; Joey J Brahim; Hein Putter; Axel R Wintzen; Jan J Verschuuren
Journal:  J Neurol       Date:  2003-06       Impact factor: 4.849

View more
  9 in total

1.  Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.

Authors:  Ethan G Hughes; Xiaoyu Peng; Amy J Gleichman; Meizan Lai; Lei Zhou; Ryan Tsou; Thomas D Parsons; David R Lynch; Josep Dalmau; Rita J Balice-Gordon
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

2.  Hu-antibody-positive patients with or without cancer have similar clinical profiles.

Authors:  A Lladó; A F Carpentier; J Honnorat; P Sillevis-Smitt; A Twijnstra; Y Blanco; I K Hart; A Saiz; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08       Impact factor: 10.154

Review 3.  Voltage gated calcium channel antibody-related neurological diseases.

Authors:  Can Ebru Bekircan-Kurt; Eda Derle Çiftçi; Aslı Tuncer Kurne; Banu Anlar
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 4.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

Review 5.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

6.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.

Authors:  Eric Lancaster; Meizan Lai; Xiaoyu Peng; Ethan Hughes; Radu Constantinescu; Jeffrey Raizer; Daniel Friedman; Mark B Skeen; Wolfgang Grisold; Akio Kimura; Kouichi Ohta; Takahiro Iizuka; Miguel Guzman; Francesc Graus; Stephen J Moss; Rita Balice-Gordon; Josep Dalmau
Journal:  Lancet Neurol       Date:  2009-12-02       Impact factor: 44.182

7.  Lambert-eaton myasthenic syndrome.

Authors:  Maria B Weimer; Joaquin Wong
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

8.  Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members.

Authors:  Elisabeth A Cats; Anne Suzanne Bertens; Jan H Veldink; Leonard H van den Berg; W Ludo van der Pol
Journal:  J Neurol       Date:  2011-11-23       Impact factor: 4.849

Review 9.  Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome.

Authors:  Arsalan Anwar; Sidra Saleem; Mirza Fawad Ahmed; Sara Ashraf; Sameen Ashraf
Journal:  Cureus       Date:  2019-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.